San Francisco, California, 94117, United States
NCT Number: NCT02565732
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
This is a safety and efficacy study of botulinum toxin type A in subjects with primary axillary hyperhidrosis.
Looking for future studies?
Notify MeKey information
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Primary axillary hyperhidrosis
- Female or male, 18 years of age or older in good general health
- Excessive sweating interferes with daily life activities and scores 3 or 4 on the HDSS at Screening and Baseline
- Axillary sweat production of at least 50 mg/5 min measured gravimetrically
Exclusion criteria
- Any neurological condition, that may place the subject at increased risk with exposure to botulinum toxin type A such as amyotrophic lateral sclerosis and motor neuropathy, Lambert-Eaton syndrome, and Myasthenia gravis
- Muscle weakness or paralysis, particularly in the upper extremities
- Active skin disease or irritation or disrupted barrier at the treatment area
- Undergone any procedures which may affect the axillary areas
- Treatment with botulinum toxin type A in the axilla in the last 9 months or anywhere in the body in the last 6 months
- Any prior axillary use of an anti-hyperhidrosis medical device
- If menopausal had symptoms of menopause such as sweating or flushing within the last year
Treatment and study plan
Botulinum toxin type A
BiologicalBotulinum toxin type A, Dose A, Topical
Placebo comparator
BiologicalPlacebo, Dose C, Topical
Primary outcomes
-
Hyperhidrosis Disease Severity Scale (HDSS)
Time frame: Week 4
Improvement at follow-up in the experimental groups compared to the placebo group
-
Gravimetry
Time frame: Week 4
The amount of sweat measured gravimetrically
Secondary outcomes
-
Dermatology Life Quality Index (DLQI)
Time frame: Week 4
Sponsors and collaborators
Lead sponsor
Revance Therapeutics, Inc.
Industry
Registry information
Important dates
- Study start
- 2015
- Primary completion
- 2015
- Study completion
- 2016
- First posted
- Oct 1, 2015
- Registry last updated
- Aug 4, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Qbrexza Cloths for Hyperhidrosis of Amputation Sites
NCT04924036
Amputation, Hyperhidrosis
Murray, Utah, United States
View Trial DetailsTreatment of Hyperhidrosis With Oxybutynin
NCT01855256
Hyperhidrosis, Skin Diseases
Morlaix, France
View Trial DetailsComparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
NCT02129660
Hyperhidrosis, Skin Diseases
Encinitas, California, United States
View Trial DetailsA Non-Interventional Study To Assess Sweating
NCT02552199
Hyperhidrosis, Skin Diseases
Carpinteria, California, United States
View Trial Details